Logos Global Management’s Celldex Therapeutics CLDX Stock Holding History

Logos Global Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$78.1M	Buy	2,100,000 +1,650,000	+367%	+$53.3M	3.36%	9
2026 Q1	$14.3M	Buy	450,000 +100,000	+29%	+$2.73M	0.71%	41
2025 Q4	$9.51M	Buy	+350,000	New	+$9.22M	0.57%	43
2025 Q3	–	Sell	-600,000	Closed	-$12.2M	–	63
2025 Q2	$12.2M	Buy	+600,000	New	+$11.7M	1.35%	25
2024 Q4	–	Sell	-900,000	Closed	-$30.6M	–	53
2024 Q3	$30.6M	Buy	+900,000	New	+$34.3M	3.3%	9
2024 Q2	–	Sell	-650,000	Closed	-$27.3M	–	62
2024 Q1	$27.3M	Buy	+650,000	New	+$26.7M	2.21%	15
2020 Q4	–	Sell	-1,200,000	Closed	-$17.8M	–	60
2020 Q3	$17.8M	Sell	1,200,000 -800,000	-40%	-$9.37M	2.28%	13
2020 Q2	$26M	Buy	+2,000,000	New	+$8.86M	5.2%	3

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Logos Global Management's CLDX Position: Q2 2026 in Review

Logos Global Management increased its Celldex Therapeutics (CLDX) stake by 367% in Q2 2026, buying an estimated $53.3M and bringing the position to 2,100,000 shares worth $78.1M. The position accounts for 3.36% of the portfolio, ranked #9.

Logos Global Management first reported a position in CLDX in Q2 2020 and has held it in 8 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Logos Global Management held 2,100,000 shares of Celldex Therapeutics worth $78.1M as of Q2 2026.
Logos Global Management bought 1,650,000 Celldex Therapeutics shares in Q2 2026, an estimated $53.3M.
Celldex Therapeutics made up 3.36% of Logos Global Management's portfolio in Q2 2026, its #9 holding.
Logos Global Management first reported a position in Celldex Therapeutics in Q2 2020 and has held it in 8 quarters since.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.